Table 1. Comparison of circulating levels of FGF19 and FGF21 between diabetic (T2D) and non-diabetic (No-T2D) patients.
| Diabetes Status | N | Mean | Std Dev | Median | LowerQuartile | UpperQuartile | |
|---|---|---|---|---|---|---|---|
| FGF19 | No-T2D | 29 | 201.91 | 142.88 | 162.61 | 101.58 | 258.86 |
| FGF19 | T2D | 46 | 122.92 | 104.13 | 94.04 | 44.73 | 147.04 |
| FGF21 | No-T2D | 22 | 393.28 | 247.63 | 363.85 | 205.27 | 471.83 |
| FGF21 | T2D | 46 | 704.51 | 792.91 | 524.44 | 233.31 | 817.93 |
Diabetic patients had signifciantly lower FGF19¶ serum levels (pg/mL), and higher (trending) FGF21§ serum levels (pg/mL). P-values according to the Wilcoxon Rank sum test (¶: P-value, 0.0036; §: P-value, 0.0871).